Companies: 10,795·Total market cap: $144.5T

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc.

DNANYSEHealthcare● Active

$8.23

+$0.01(+0.12%)

Market Cap$537620602

P/E Ratio—

52W High$17.58

52W Low$5.37

Avg Volume1.2M

Open$8.40

Beta1.80

Net Income Financials Revenue

Ginkgo Bioworks Holdings, Inc. (DNA) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

DNA · net income · updated Jun 8, 2026

Core profitability metrics

DNA · net income · margin · TTM · CAGR

Net income was −$312.8M for FY2025 (fiscal year ending 2025-12-31), up 42.8% year-over-year. Net profit margin was -183.8%.

FY2025 Net Income−$312.8M▲ +42.8% YoY

Trailing 12M (TTM)−$304.4Mtrailing 4 quarters sum

Net Profit Margin-183.8%−$312.8M ÷ $170.2M

YoY Change+42.8%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · DNA net income history · DNA profit margin

Annual net income data

DNA · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$312.8M▲ +42.8%-183.8%$170.2M

FY2024Loss−$547.0M▲ +38.7%-240.9%$227.0M

FY2023Loss−$892.9M▲ +57.6%-355.1%$251.5M

FY2022Loss−$2.10B▼ 15.0%-440.6%$477.7M

FY2021Loss−$1.83B▼ 1345.4%-583.1%$313.8M

Net income vs peers (Healthcare)

DNA vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Ginkgo Bioworks Holdings, Inc.YOU

DNA

−$312.8M+42.8%-183.8%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Ginkgo Bioworks Holdings, Inc. (DNA) reported net income of −$312.8M for FY2025 (fiscal year ending 2025-12-31), up 42.8% year-over-year. The net profit margin was -183.8% — meaning the company kept $-1.84 of every dollar of revenue as profit.

Ginkgo Bioworks Holdings, Inc. has not yet achieved annual profitability based on available data (7 fiscal years). The company has reported net losses across all available periods.

Ginkgo Bioworks Holdings, Inc.'s net profit margin was -183.8% for FY2025, based on the latest annual results.

Investors sometimes search for "Ginkgo Bioworks Holdings, Inc. net worth" — the company's market capitalization is a separate figure from DNA net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

DNA net income · 4 questions

Ginkgo Bioworks Holdings, Inc. is not currently profitable on an annual basis. The company reported a net loss of $312.8M for FY2025.

is DNA profitabledoes DNA make a profitDNA profitabilityDNA profitable company

▸ Source: FMP /income-statement · GAAP · Ginkgo Bioworks Holdings, Inc. · Ginkgo Bioworks Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026